Stock·NYSE·Healthcare
Elevance Health, Inc. (ELV)
- Market cap
- $92.88B
- P/E
- 18.82
- Dividend yield
- 1.61%
- Street target
- $463.00median of 22 analysts
- 52-week range
- $274.84 $436.24
The short version
Where ELV stands today, in four lines, and what CleaRank Financial AI makes of it.
ELV at a glance
Elevance Health, Inc. (ELV): Strong Buy, 80/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($403.84 and $369.22).
- Earnings ELV beat estimates in 4 of its last 7 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $3.7M and bought $5.1M over the last 18 months.
- Valuation P/E of 18.8 against 31.9 for the Healthcare sector: a discount to peers (-41%).
Figures as of October 18, 2026.
CleaRank Financial AI
Elevance Health, Inc. (ELV) carries a CleaRank rating of Strong Buy and a model score of 80/100.
Trend contributes the most to that score: the price is 15.99% above its 200-day average and 6.05% above its 50-day average, while the 50-day average sits 9.38% above the 200-day. Revenue growth pulls hardest in the other direction, with revenue up 1.40%, 6.7 percentage points slower than the sector median. The 50-day average is $403.84, the 200-day is $369.22, and the price rose 23.00% over the past year.
Only on CleaRank
Figures we compute ourselves from ELV's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $428.26 is 6.0% above the 50-day simple moving average of $403.84.Price above its 200-day average ›
The price is 16.0% above the 200-day simple moving average of $369.22.50-day average above the 200-day ›
The 50-day average ($403.84) is 9.4% above the 200-day average ($369.22), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 95% of its 52-week range, between $274.84 and $436.24.
ELV share price
Pick a period: each tab shows how far ELV has moved over it, to the last close.
Today's trading
Where ELV sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 18.82 is 41.0% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 0.46 is 86.4% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $5.0B on revenue of $201.1B, a net margin of 2.5%.Beat estimates in most recent reports ›
ELV beat the EPS estimate in 4 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 1.61%, or $6.87 a share a year.
Key statistics
The headline figures for ELV.
As of October 18, 2026, ELV trades at $428.26, with a market value of $92.88B, a P/E ratio of 18.82 and a dividend yield of 1.61%.
What the numbers say
CleaRank Financial AI's reading of ELV's valuation, growth and risks.
ELV trades at 18.82 times trailing earnings, which puts its P/E 41.0% below the Healthcare median of 31.9. The peer comparison on this page rates that P/E as a discount to peers. On sales, the P/S of 0.46 sits 86.5% below the sector median of 3.4. For context, the company has a market value of $92.9B and trailing earnings of $22.76 per share.
ELV's revenue rose 1.40% in the latest year, trailing the 8.1% Healthcare sector median by 6.7 percentage points. Its net margin stands at 2.47% and its operating margin at 4.56%. Return on equity is 11.13%, which is above the sector median of 7.3%. Debt-to-equity is 0.69, and the trailing dividend yield is 1.61%, equal to $6.87 a share each year.
ELV's most recent quarterly report, dated July 15, 2026, showed EPS of $7.45 against the $6.21 analysts had forecast. That beat the estimate by 19.97%. Still, the share price dropped 4.48% in the first session after the report.
Over its last 7 reports, ELV topped the estimate 4 times, but beats have not guaranteed gains: the stock fell the next day after 2 of them. The largest of the earlier reactions came after the July 17, 2025 report, which missed the estimate by 0.90% while the stock fell 8.38%. Analysts' average EPS estimate for this fiscal year is $27.23, which would be a decline of 10.1%, and $29.59 for next year (growth of 8.7%).
Normal swings for ELV run at about 1.52% a day. Over the last 18 months, insider sales totalled $3.7M against $5.1M of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
ELV against the Healthcare sector
How ELV compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ELV trades at a notable discount to sector peers (-41%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, ELV has gained 3.5% against a gain of 31.6% for XLV.
Performance against XLV
ELV and the Healthcare sector fund over the same days.
Revenue and earnings
How much ELV sells, and how much of it becomes profit.
Revenue growth: Revenue grew 12.6% in FY2025 to $199B, from $177B a year earlier.
Profit margin: The net margin was 2.8% in FY2025, down from 3.4% the year before.
Profitable: ELV earned $5.7B in FY2025.
Earnings reality check
Did ELV beat what analysts expected, and how did the stock react?
Earnings record: ELV beat the analyst estimate in 4 of the last 7 quarters.
Market reaction: The stock fell in the first session after 2 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 15, 2026after close | $6.21 | $7.45 | +19.97% | -4.48% | -0.32% |
| Apr 22, 2026after close | $10.81 | $12.58 | +16.37% | +5.51% | +14.76% |
| Oct 21, 2025after close | $4.94 | $6.03 | +22.06% | -1.30% | -2.96% |
| Jul 17, 2025after close | $8.92 | $8.84 | -0.90% | -8.38% | -7.28% |
| Apr 22, 2025after close | $11.48 | $11.97 | +4.27% | +2.64% | -0.54% |
| Jan 23, 2025after close | $3.85 | $3.84 | -0.26% | -0.10% | -0.51% |
| Oct 17, 2024after close | $9.65 | $8.37 | -13.26% | -3.06% | -5.70% |
As of October 18, 2026, ELV has beaten the analyst EPS estimate in 4 of its last 7 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on July 15, 2026, came in 19.97% above the estimate and the stock moved -4.48% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 67.0, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 67.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of ELV
The score, the reasoning behind it, and what could move the price next.
ELV is trending up. The stock trades at $428.26, which is 6.05% above its 50-day average of $403.84 and 15.99% above its 200-day average of $369.22. Sitting at 95% of its 52-week range, the price is 1.83% below the 52-week high of $436.24. The 50-day average is 9.38% above the 200-day average, meaning the shorter trend is pulling ahead of the longer one.
On momentum, the 14-day RSI reads 67.0, in the bullish zone, below the overbought line, with the MACD line positive. Every period on the chart shows a gain, with the price up 14.78% over the past three months, 32.57% over the past six months and 23.00% over the past year.
Earnings beat ›
The July 15, 2026 report beat the EPS estimate by 19.97%, and the share price fell 4.48% in the first session after it.
Source: Earnings report, July 15, 2026
Rating reaffirmed ›
Barclays kept its Overweight rating on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- Keep an eye on the two closest levels: the 52-week high at $436.24 overhead and the 20-day EMA at $410.69 underneath.
- A 14-day RSI of 67.0 in the bullish zone, paired with a positive MACD line, describes the current momentum. Readings above 70 or below 30 would signal stretched momentum.
- The share price dropped 4.48% in the first session after the July 15, 2026 report, even though ELV beat estimates in 4 of the last 7 reports.
ELV is above its 50-day and 200-day moving averages ($403.84 and $369.22), at $403.84 and $369.22, and that keeps the trend up. A drop through the 50-day average would be the first sign of weakness. The closest support beneath the price is the 20-day EMA, at $410.69.
The next level overhead for ELV is the 52-week high at $436.24. The RSI is in the bullish band, which backs the current direction, though it is near the overbought line.
Technical indicators
Momentum and trend for ELV, from its daily closes.
As of October 18, 2026, with ELV at $428.26, its 14-day RSI is 67.0 (showing bullish momentum without being overbought), its 50-day simple moving average is $403.84 and its 200-day is $369.22.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ELV moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, ELV's 1-year correlation of daily returns is +0.10 with S&P 500 (SPY), +0.03 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and +0.02 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
15 of 22 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $463.00 is 8.1% above the price.More buy ratings than three months ago ›
15 of 22 rate it a buy now, against 15 of 22 three months ago.
ELV Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Jul 17, 2026 | Bernstein | Maintains | Outperform |
| Jul 17, 2026 | Leerink Partners | Maintains | Market Perform |
| Jul 16, 2026 | RBC Capital | Maintains | Sector Perform |
| Jul 16, 2026 | Wells Fargo | Maintains | Overweight |
| Jul 16, 2026 | Guggenheim | Maintains | Buy |
As of October 18, 2026, 22 Wall Street analysts cover ELV: 15 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $393.00 to $492.00, with a median of $463.00, 8.1% above the price of $428.26.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ELV trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ELV's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ELV tends to move, against the market and on its own.
The long record
ELV's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.52% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 50.1%, from September 2024 to August 2025; the price is still 20.7% below that peak.Most 1-year holds ended higher ›
68% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $39,885, against $41,793 in the S&P 500 (SPY).
ELV Drawdowns & Recovery
As of October 18, 2026, ELV's worst peak-to-trough fall over the last 10 years with dividends reinvested was -50.1% (September 2024 to August 2025); it is still 20.7% below that peak, and 68% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ELV in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ELV trailed the S&P 500 over this period: $39,885 against $41,793.
A $10,000 investment in ELV in October 2016 would be worth about $39,885 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ELV, and which have not.
Strongest month, April: an average of +5.55%, up in 7 of 10 years.
Weakest month, September: an average of -2.23%, up in 3 of 10 years.
This month, October: has averaged +4.81%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ELV's strongest calendar month has been April (average +5.55%, up in 7 of 10 years) and its weakest September (average -2.23%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ELV, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ELV today could grow to about $23,200 by 2036 in the base case, with a 90th-percentile outcome near $82,598 and a 10th-percentile outcome around $6,516. The simulation models price only; at today's 1.61% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ELV Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $600 for ELV by 2030 in the base case, from $428 today (1.4x over 4 years). The 10th-percentile path ends near $269. These are outcomes of a Monte Carlo simulation run on ELV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $312 | $466 | $696 | |
| 2028 | $287 | $507 | $894 | |
| 2029 | $275 | $551 | $1,105 | |
| 2030 | $269 | $600 | $1,339 | |
| 2031 | $266 | $652 | $1,601 |
Method: a lognormal simulation of ELV's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ELV insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $5.1M on the open market and sold $3.7M.
As of October 18, 2026, ELV insiders reported 6 open-market sales worth $3.7M and 5 open-market purchases worth $5.1M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Mark Kaye
Chief Financial Officer
|
Grant | 2.6K | - |
| Jul 17, 2026 | Gail A Koziara Boudreaux
Chief Executive Officer
|
Buy | 2.7K | $1.0M |
| Jul 17, 2026 | Ramiro G Peru
Director
|
Buy | 1.0K | $366.1K |
| Jun 12, 2026 | Ronald W Penczek
Officer
|
Sell | 369 | $148.8K |
| Jun 11, 2026 | Robert L Dixon Jr
Director
|
Sell | 151 | $60.7K |
| May 19, 2026 | Ronald W Penczek
Officer
|
Sell | 1.5K | $617.2K |
| May 19, 2026 | Ronald W Penczek
Officer
|
Option | 1.5K | $450.6K |
| May 13, 2026 | Steven Howard Collis
Director
|
Grant | 563 | - |
| May 13, 2026 | Susan D Devore
Director
|
Grant | 563 | - |
| May 13, 2026 | Robert L Dixon Jr
Director
|
Grant | 563 | - |
| May 13, 2026 | Lewis Hay III
Director
|
Grant | 563 | - |
| May 13, 2026 | Bahija Jallal
Director
|
Grant | 563 | - |
| May 13, 2026 | Antonio F Neri
Director
|
Grant | 563 | - |
| May 13, 2026 | Ramiro G Peru
Director
|
Grant | 563 | - |
| May 13, 2026 | Ryan M. Schneider
Director
|
Grant | 563 | - |
| May 13, 2026 | Amy W. Schulman
Director
|
Grant | 563 | - |
| May 13, 2026 | Deanna D Strable-Soethout
Director
|
Grant | 563 | - |
| Mar 12, 2026 | Amy W. Schulman
Director
|
Sell | 26 | $7.5K |
| Mar 6, 2026 | Charles Morgan Kendrick Jr
Officer
|
Sell | 3.2K | $910.6K |
| Mar 5, 2026 | Steven Howard Collis
Director
|
Buy | 3.0K | $869.5K |
| Mar 2, 2026 | Gail Koziara Boudreaux
Chief Executive Officer
|
Grant | 26.7K | - |
| Mar 2, 2026 | Ryan R Craig
Officer
|
Grant | 3.0K | - |
| Mar 2, 2026 | Peter D Haytaian
Officer
|
Grant | 2.9K | - |
| Mar 2, 2026 | Mark Kaye
Chief Financial Officer
|
Grant | 16.6K | - |
| Mar 2, 2026 | Charles Morgan Kendrick Jr
Officer
|
Grant | 6.5K | - |
| Mar 2, 2026 | Ratnakar Lavu
Chief Technology Officer
|
Grant | 11.9K | - |
| Mar 2, 2026 | Felicia F. Norwood
Officer
|
Grant | 8.8K | - |
| Mar 2, 2026 | Ronald W Penczek
Officer
|
Grant | 2.4K | - |
| Mar 2, 2026 | Erin M Wessling
Officer
|
Grant | 3.0K | - |
| Feb 2, 2026 | Amy W. Schulman
Director
|
Grant | 218 | - |
| Sep 2, 2025 | Ryan R Craig
Officer
|
Grant | 970 | - |
| Sep 2, 2025 | Erin M Wessling
Officer
|
Grant | 931 | - |
| Aug 19, 2025 | Susan D Devore
Director
|
Buy | 1.2K | $374.6K |
| Aug 1, 2025 | Steven H Collis
Director
|
Grant | 639 | - |
| Jul 18, 2025 | Gail A Koziara Boudreaux
Chief Executive Officer
|
Buy | 8.5K | $2.4M |
| May 14, 2025 | Ronald Kerry Clark
Director
|
Grant | 601 | - |
| May 14, 2025 | Susan D Devore
Director
|
Grant | 601 | - |
| May 14, 2025 | Robert L Dixon Jr
Director
|
Grant | 601 | - |
| May 14, 2025 | Lewis Hay III
Director
|
Grant | 601 | - |
| May 14, 2025 | Bahija Jallal
Director
|
Grant | 601 | - |
| May 14, 2025 | Antonio F Neri
Director
|
Grant | 601 | - |
| May 14, 2025 | Ramiro G Peru
Director
|
Grant | 601 | - |
| May 14, 2025 | Ryan M. Schneider
Director
|
Grant | 601 | - |
| May 14, 2025 | Deanna D Strable-Soethout
Director
|
Grant | 601 | - |
| Apr 24, 2025 | Mark Kaye
Chief Financial Officer
|
Sell | 4.6K | $1.9M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.